HYUNDAI BIOSCIENCE CO., LTD.
Develops antiviral and anticancer drugs using a proprietary drug delivery system.
048410 | KO
Overview
Corporate Details
- ISIN(s):
- KR7048410005
- LEI:
- Country:
- South Korea
- Address:
- 경상북도 김천시 아포읍 아포공단길 106, 김천시
Description
HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-03-14 00:00 |
주주총회소집결의
|
Korean | 14.9 KB | ||
| 2022-03-14 00:00 |
주주총회소집공고
|
Korean | 105.1 KB | ||
| 2022-03-14 00:00 |
의결권대리행사권유참고서류
|
Korean | 110.3 KB | ||
| 2022-02-24 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | 13.7 KB | ||
| 2022-02-09 00:00 |
투자판단관련주요경영사항(코로나-19 치료제 CP-COV03의 국내 제1상 임상시험 결과)
|
Korean | 11.5 KB | ||
| 2022-01-21 00:00 |
투자판단관련주요경영사항(COVID-19 치료제 CP-COV03의 제2상 임상시험계획 신청서 제출)
|
Korean | 10.0 KB | ||
| 2022-01-11 00:00 |
주식매수선택권부여에관한신고
|
Korean | 25.2 KB | ||
| 2021-12-16 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2021-11-15 00:00 |
분기보고서 (2021.09)
|
Korean | 1.1 MB | ||
| 2021-11-11 00:00 |
투자판단관련주요경영사항(COVID-19 치료제 CP-COV03의 1상 임상시험계획 승인)
|
Korean | 8.7 KB | ||
| 2021-10-05 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.4 KB | ||
| 2021-10-05 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 108.2 KB | ||
| 2021-09-30 00:00 |
투자판단관련주요경영사항(COVID-19 치료제 CP-COV03의 1상 임상시험계획 신청서 제출)
|
Korean | 8.6 KB | ||
| 2021-09-27 00:00 |
전환청구권행사
|
Korean | 10.5 KB | ||
| 2021-09-23 00:00 |
전환청구권행사
|
Korean | 9.1 KB |
Automate Your Workflow. Get a real-time feed of all HYUNDAI BIOSCIENCE CO., LTD. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for HYUNDAI BIOSCIENCE CO., LTD.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for HYUNDAI BIOSCIENCE CO., LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
